Heart Research, Murdoch Children's Research Institute, Parkvile, Victoria, Australia
Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia.
BMJ Open. 2022 Jul 7;12(7):e057622. doi: 10.1136/bmjopen-2021-057622.
Extremely preterm (EP)/extremely low birthweight (ELBW) individuals may have an increased risk for adverse cardiovascular outcomes. Compared with term-born controls, these individuals have poorer lung function and reduced exercise capacity. Exercise interventions play an important role in reducing cardiopulmonary risk, however their use in EP/ELBW cohorts is unknown. This study, cardiac cycle, aims to characterise the cardiopulmonary system of children and adolescents who were born EP compared with those born at term, following acute and chronic exercise bouts.
The single-centre study comprises a home-based exercise intervention, with physiological characterisation at baseline and after completion of the intervention. Fifty-eight children and adolescents aged 10-18 years who were born EP and/or with ELBW will be recruited. Cardiopulmonary function assessed via measures of blood pressure, arterial stiffness, capillary density, peak oxygen consumption, lung clearance indexes and ventricular structure/function, will be compared with 58 age-matched and sex-matched term-born controls at baseline and post intervention. The intervention will consist of a 10-week stationary cycling programme, utilising Zwift technology.
The study is approved by the Ethics Committee of the Royal Children's Hospital Melbourne under HREC2019.053. Results will be disseminated via peer-reviewed journal regardless of outcome.
12619000539134, ANZCTR.
极早产儿(EP)/极低出生体重儿(ELBW)发生不良心血管结局的风险可能增加。与足月出生的对照组相比,这些个体的肺功能较差,运动能力降低。运动干预在降低心肺风险方面发挥着重要作用,但在 EP/ELBW 队列中的应用尚不清楚。本研究,心脏周期,旨在描述与足月出生的对照组相比,经历急性和慢性运动后,出生 EP 的儿童和青少年的心肺系统特征。
该单中心研究包括一项基于家庭的运动干预,在干预完成前后进行生理特征描述。将招募 58 名年龄在 10-18 岁之间的 EP 和/或 ELBW 出生的儿童和青少年。通过血压、动脉僵硬度、毛细血管密度、最大摄氧量、肺清除指数和心室结构/功能的测量来评估心肺功能,将在基线和干预后与 58 名年龄和性别匹配的足月出生对照组进行比较。干预将包括 10 周的固定自行车计划,利用 Zwift 技术。
该研究已获得墨尔本皇家儿童医院伦理委员会的批准,注册号为 HREC2019.053。无论结果如何,研究结果都将通过同行评审的期刊传播。
12619000539134,ANZCTR。